Abstract
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Brain Neoplasms / drug therapy*
-
Disease Progression
-
Disease-Free Survival
-
Female
-
Glioblastoma / drug therapy*
-
Humans
-
Lomustine / administration & dosage
-
Male
-
Middle Aged
-
Procarbazine / administration & dosage
-
Recurrence
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Procarbazine
-
Vincristine
-
Lomustine